Industries > Pharma > Global Hypertension Drugs Market 2019-2029

Back to Pharma Reports

Global Hypertension Drugs Market 2019-2029

Angiotensin II Receptor Blockers (ARBs), Angiotensin-converting Enzyme (ACE) Inhibitors, Beta Blockers, Calcium Channel Blockers (CCBs), Diuretics, Fixed-dose Combinations (FDCs)

PUBLISHED: 31 July 2019

PAGES: 145

PRODUCT CODE: PHA0457

SUBMARKET: Therapeutic Drugs

SKU: PHA0457 Categories: Pharma, Therapeutic Drugs Tag: PHA0457

The global hypertension drugs market is estimated to have reached $24.7bn in 2018 and is expected to reach the market value of $19.3bn by 2029 with a CAGR of -2.3% from 2019 to 2029.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 146-page report you will receive 118 charts– all unavailable elsewhere.

The 146-page report provides clear detailed insight into the hypertension drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Global Hypertension Drugs Market forecasts from 2019-2029

• Global Pulmonary Arterial Hypertension (PAH) Market forecasts from 2019-2029

• Revenue forecasts for the Hypertension Drugs by Class of Drug from 2019-2029:
• Angiotensin II Receptor Blockers (ARBs): further broken down into revenue forecast of Atacand, Avapro, Diovan, Cozaar, Benicar, Entresto, Micardis, Azilva, Candesartan
• Angiotensin-converting Enzyme (ACE) Inhibitor: further broken down into revenue forecast of Tritace
• Beta-Blockers: further broken down into revenue forecast of Seloken/Toprol-XL, Coreg CR, Concor
• Calcium Channel Blockers (CCBs): further broken down into revenue forecast of Norvasc, Plendil, Adalat, Amlodin
• Diuretics
• Fixed-dose Combinations (FDC): further broken down into revenue forecast of Azor, Tribenzor, Exforge, Tekturna HCT, others

• Revenue forecasts for the leading PAH drugs from 2019-2029:
• Tacleer
• Uptravi
• Opsumit
• Letairis
• Adcirca
• Revatio
• Adempas
• Veletri
• Oremitram
• Tyvaso
• Remodulin

• Revenue forecasts for the Hypertension Drugs by Regional and National Market from 2019-2029:
• U.S.
• Canada
• Mexico
• Germany
• France
• UK
• Spain
• Italy
• Rest of Europe
• Russia
• Japan
• China
• India
• Rest of Asia
• Brazil
• South Africa
• Rest of the World

• Profiles and discussion on the leading companies of the hypertension drugs market:
• Actelion
• AstraZeneca
• Boehringer Ingelheim GmbH
• Daiichi Sankyo
• Johnson & Johnson Company
• Merck & Co.
• Novartis
• Pfizer
• Sanofi Aventis
• United Therapeutics

• Analysis of the Drivers, Restraints, Opportunities and Porter’s Five Forces analysis of the global hypertension drugs market

• Key Questions Answered by this Report:
• How is the Hypertension Drugs market evolving?
• What is driving and restraining the Hypertension Drugs market dynamics?
• How will each of the submarkets grow over the forecast period and how much revenue will these submarkets account for in 2029?
• How will the market shares for each of the Hypertension Drugs submarkets develop from 2019 to 2029?
• What will be the main driver for the overall market from 2019-2029?
• How will political and regulatory factors influence the regional markets and submarkets?
• How will the market shares of the national markets change by 2029 and which geographical region will lead the market in 2029?
• Who are the leading players and what are their prospects over the forecast period?
• How will the industry sector evolve during the period between 2019 and 2029?

Visiongain’s study is intended for anyone requiring commercial analyses for the Global Hypertension Drugs Market. You find data, trends and predictions.

Buy our report today Hypertension Drugs Market Analysis of 2019-2029: Angiotensin II Receptor Blockers (ARBs), Angiotensin-converting Enzyme (ACE) Inhibitors, Beta Blockers, Calcium Channel Blockers (CCBs), Diuretics, Fixed-dose Combinations (FDCs).

Visiongain is a trading partner with the US Federal Government
CCR Ref number KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help sara.peerun@visiongain.com

1. Report Overview

1.1 Global Hypertension Drugs Market Overview

1.2 Overview of Findings

1.3 Global Hypertension Drugs Market Segmentation, 2019

1.4 Structure of the Report

1.5 How This Report Delivers

1.6 Key Questions Answered by This Analytical Report

1.7 Who is This Report For?

1.8 Methodology

1.9 Frequently Asked Questions (FAQ)

1.10 Associated Visiongain Reports

1.11 About Visiongain

2. Introduction to the Hypertension Drugs Market

2.1 An Overview of Hypertension

2.2 Causes of Hypertension

2.3 Primary Hypertension

2.4 Secondary Hypertension

2.5 Pulmonary Hypertension

2.6 Epidemiology of Hypertension

2.7 Links with Other Disorders

2.8 Treatment of Hypertension

2.9 Treatment Targets and the Selection of Drugs

3. Hypertension Drugs Market Overview, 2018

3.1 Market Definition and Segments covered:

3.2 Global Hypertension Drugs Market Segmentation

3.3 Market Size and Growth Prospects

3.4 Hypertension Drugs Market Dynamics (Drivers & Restraints)

3.4.1 Drivers

3.4.1.1 Rising Prevalence of Hypertension to boost the market growth

3.4.1.2 Rising complications of untreated blood pressure

3.4.1.3 Growing government and private initiatives to prevent and treat hypertension

3.4.2 Restraints

3.4.2.1 Tough generic competition due to patent expiry

3.4.2.2 Rising non-pharmacological treatment

3.4.3 Opportunities

3.4.3.1 Introduction of novel approaches for the treatment of hypertension

3.5 Hypertension Market Industry Analysis

3.5.1 Porter’s Five Force Analysis

3.5.1.1 Rivalry among Competitors [High]

3.5.1.2 Threat of New Entrants [Low]

3.5.1.3 Power of Suppliers [High]

3.5.1.4 Power of Buyers [Medium]

3.5.1.5 Threat of Substitutes [Low]

3.6 Value Chain Analysis

3.6.1 Manufacturer of medicine:

3.6.2 Wholesalers:

3.6.3 Pharmacy:

3.6.4 Health Plans and Pharmacy Benefit Managers (PBMs):

3.7 Opportunity Analysis

3.7.1 PAH (Pulmonary Arterial Hypertension Market)

4. Hypertension Drugs Market by Types, 2019-2029

4.1 Introduction

4.2 Beta Blockers

4.3 Angiotensin Converting Enzyme (ACE) Inhibitors

4.4 Calcium Channel Blockers (CCBs)

4.5 Angiotensin II Receptor Blocker (ARBs)

4.6 Diuretics

4.7 Fixed Dose Combination (FDCs)

4.8 Prospects for Hypertension Patients

5. Pulmonary Arterial Hypertension (PAH), 2019-2029

6. The Leading National Hypertension Drugs Market, 2019-2029

6.1 The Leading National Hypertension Drugs Market, 2018

6.2 The Leading National Hypertension Drugs Market, 2029

6.3 Leading National Hypertension Drugs Market Forecast, 2019-2029

6.4 The US Hypertension Drugs Market Forecast, 2019-2029

6.5 The Canadian Hypertension Drugs Market Forecast, 2019-2029

6.6 The Mexican Hypertension Drugs Market Forecast, 2019-2029

6.7 The European Hypertension Drugs Market, 2019-2029

6.7.1 EU Hypertension Drugs Market Forecast, 2019-2029

6.7.1.1 The German Hypertension Drugs Market Forecast 2019-2029

6.7.1.2 The French Hypertension Drugs Market Forecast 2019-2029

6.7.1.3 The UK Hypertension Drugs Market Forecast, 2019-2029

6.7.1.4 The Italian Hypertension Drugs Market Forecast, 2019-2029

6.7.1.5 The Spanish Hypertension Drugs Market Forecast, 2019-2029

6.7.1.6 Rest of Europe (RoE) Hypertension Drugs Market Forecast, 2019-2029

6.8 Japanese Hypertension Drugs Market Forecast, 2019-2029

6.9 The Chinese Hypertension Drugs Market Forecast, 2019-2029

6.10 The Indian Hypertension Drugs Market Forecast, 2019-2029

6.11 The Rest of Asia (ROA) Hypertension Drugs Market Forecast, 2019-2029

6.12 Russian Hypertension Drugs Market Forecast, 2019-2029

6.13 The Brazilian Hypertension Drugs Market Forecast, 2019-2029

6.14 South Africa Hypertension Drugs Market Forecast, 2019-2029

6.15 RoW Hypertension Drugs Market Forecast, 2019-2029

7. Leading Companies in Hypertension Drugs Market 2019-2029

7.1 Actelion (now a Johnson & Johnson company)

7.1.1 Financial Performance

7.1.2 Product Sales Performance

7.1.3 PAH Product Sales Performance

7.1.4 Merger and Acquisition

7.2 Johnson & Johnson Company

7.2.1 Merger and Acquisition

7.2.2 New Drug Development for Resistant Hypertension

7.3 AstraZeneca

7.3.1 Financial Performance

7.3.2 Financial Performance by Segments

7.3.3 Major Cardiovascular Products

7.3.4 Anti-Hypertension Products and Patent Status

7.3.5 Anti-Hypertension Products Sales by Region

7.3.6 Recent Developments

7.4 Sanofi Aventis

7.4.1 Financial Performance

7.4.1.1 Financial Performance by Segments

7.5 Daiichi Sankyo

7.5.1 Financial Performance

7.5.2 Products

7.6 Novartis

7.6.1 Financial Performance by Business Segments

7.6.2 Products

7.6.3 Pipeline Products

7.7 Pfizer

7.7.1 Pfizer Financial Performance, 2015-2017

7.7.2 Products- PAH

7.8 Merck & Co.

7.8.1 Merck &Co. Financial Performance, 2015-2017

7.9 Boehringer Ingelheim GmbH

7.9.1 Financial Performance, 2016-2017

7.10 United Therapeutics

7.10.1 Financial Performance, 2015-2017

7.10.2 Financial Performance by Geography, 2015-2017

8. Pipeline Developments in Hypertension

9. Conclusions & Recommendations

10. Key Findings

10.1 Market Snapshot: World Hypertension Drugs Market (2019 & 2029)

10.2 Market Drivers & Restraints

Appendices

Associated Visiongain Reports

Visiongain Report Sales Order Form

About Visiongain

Visiongain Report Evaluation Form

List of Tables

Table 2.1: Categories of Blood Pressure in Adults

Table 4.1 Global Beta Blockers Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029

Table 4.2 Leading Beta Blockers to treat Hypertension

Table 4.3 The Beta Blockers Market Forecast by Leading Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029

Table 4.4 The Beta Blockers Market Forecast by Generic Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029

Table 4.5 The ACE Inhibitors Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029

Table 4.6 Leading ACE Inhibitors to treat Hypertension

Table 4.7 The ACE Inhibitor Market Forecast by Leading Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029

Table 4.8 The ACE Market Forecast by Generic Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029

Table 4.9 The CCBs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029

Table 4.10 Leading Calcium Channel Blockers to treat Hypertension

Table 4.11 The CCBs Market Forecast by Leading Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029

Table 4.12 The CCBs Generics Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029

Table 4.13 The ARBs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029

Table 4.14 The ARBs Market Leading Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029

Table 4.15 Leading ARBs to treat Hypertension

Table 4.16 The ARBs Market Forecast of Generic Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029

Table 4.17 The Diuretics Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029

Table 4.18 The FDCS Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029

Table 4.19 The FDCs Market Leading Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029

Table 4.20 Leading FDCs to treat Hypertension

Table 4.21 The FDCs Market Forecast of Generic Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029

Table 5.1 The PAH Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029

Table 5.2 The PAH Market Forecast for Leading Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029

Table 5.3 The PAH Market Forecast for Generic Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029

Table 6.1: The Hypertension Drugs Market by Country: Revenue ($bn), and Market Share (%), 2018

Table: 6.2 The Hypertension Drugs Market by Country: Revenue ($bn), 2029

Table 6.3 The Leading National Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029

Table 6.4 The US Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029

Table 6.5 Canada Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029

Table 6.6 Mexico Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029

Table 6.7 The European Hypertension Drugs Market by Country: Revenue ($bn) and Market Share (%), 2018

Table 6.8 EU Hypertension Drugs Market by Country Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029

Table 6.9 Germany Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and

Table: 6.10 France Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029

Table 6.11. UK Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029

Table 6.12 Italy Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029

Table 6.13 Spain Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029

Table 6.14 Rest of Europe (RoE) Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029

Table 6.15 Japan Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029

Table 6.16 China Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029

Table 6.17 India Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029

Table 6.18 RoA Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029

Table 6.19 Russia Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029

Table 6.20 Brazil Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029

Table 6.21 South Africa Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029

Table 6.22 RoW Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029

Table 7.1 Actelion Revenue: Product Sales ($mn), Core R&D ($mn) and Operating Income ($mn), 2014-2016

Table 7.2 Actelion Revenue, Product Sales ($mn), 2015-2016

Table 7.3 Opsumit Revenue, Product Sales ($mn) by Region, 2015-2016

Table 7.4 Uptravi Revenue, Product Sales (USD mn), By Region, 2015-2016

Table 7.5 Veletri Revenue, Product Sales ($mn), By Region, 2015-2016

Table 7.6 Ventavis Revenue, Product Sales ($mn), By Region, 2015-2016

Table 7.7 J&J Pharmaceutical: Revenue ($bn), Revenue Share (%) by Segment, 2016 and 2017

Table 7.8 AstraZeneca Net Sales by Product Category, ($mn),2015-2017

Table 7.9 AstraZeneca’s Anti-Hypertension Drugs Portfolio and Patent Status

Table 7.10 AstraZeneca’s Anti-Hypertension Products Sales by Region, ($mn), 2015-2017

Table 7.11 Daiichi Sankyo Antihypertension Products by Business Units

Table 7.12 Novartis Pharmaceuticals by Division: Revenue ($mn), 2017

Table 7.13 Established Medicine by Division: Revenue ($mn), 2017 (Y-O-Y change in USD %)

Table 7.14 Novartis Pipeline Products for Hypertension and Clinical Trial Phase

Table 7.15 Pfizer by Division: Revenue ($mn),2015- 2017

Table 7.16 Pfizer by Geography: Revenue ($mn), 2015- 2017

Table 7.17 Pfizer for PAH: Revenue ($mn), 2015- 2017

Table 7.18 Merck & Co.: Revenue by Segments ($mn), 2015-2017

Table 7.19 Merck & Co.: Revenue, By Anti–Hypertension Products ($mn), 2015- 2017

Table 7.20 Merck & Co.: Cozaar Revenue by Geography ($mn), 2015- 2017

Table 7.21 Merck & Co.: Adempas Revenue by Geography ($mn),2015- 2017

Table 7.22 Boehringer Ingelheim: Revenue by Segments ($mn), 2015- 2017

Table 7.23 Boehringer Ingelheim: Revenue by Segments ($mn),2016- 2017

Table 7.24 Boehringer Ingelheim: Anti-Hypertension Revenue by Products ($mn), 2016- 2017

Table 7.25 United Therapeutics PAH Revenue by Products ($mn),2016- 2017

Table 7.26 United Therapeutics Revenue by Geography ($mn), 2015- 2017Table 10.1 Market Snapshot: World Ophthalmic devices Market (2019 & 2029)

List of Figures

Figure 1.1 Hypertension Drugs Market: Overview of Submarkets, 2019

Figure 3.1: Global Hypertension Drugs: Overview of Submarkets and Drugs /Classes, 2019

Figure 3.2: Global Hypertension Drugs Market: Drivers & Restraints, 2019

Figure 3.3: Porter’s Five Forces Analysis of the Hypertension Drugs Market

Figure 3.4: Value Chain Analysis Hypertension Drugs Market, 2019

Figure 4.1 Hypertension Drugs Market by Type of Drugs: Market Share (%), 2018

Figure 6.1 The Hypertension Drugs Market by Region: Revenue ($bn), 2018

Figure 6.2: The Hypertension Drugs Market by Region: Market Share (%), 2018

Figure: 6.3 The Hypertension Drugs Market by Country: Revenue ($bn), (%), 2029

Figure 6.4 The Hypertension Drugs Market by Country: Market Share (%), 2029

Figure: 6.5 The US Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 6.6 Canada Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 6.7 Mexico Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 6.8 EU Hypertension Drugs Market by Country: Revenue ($bn), 2018

Figure 6.9 EU Hypertension Drugs Market by Country: Market Share (%), 2018

Figure 6.10 EU Hypertension Drugs Market Forecast by Country: Revenue ($bn) and AGR (%), 2019-2029

CAGR (%), 2019-2029

Figure 6.11 Germany Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 6.12 France Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 6.13 UK Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 6.14 Italy Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 6.15 Spain Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 6.16 The ROE Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 6.17 Japan Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 6.18 China Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 6.19 India Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 6.20 RoA Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 6.21 The Russia Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 6.22 Brazil Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 6.23 South Africa Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 6.24 RoW Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 7.1 AstraZeneca Financial Performance ($mn), 2015-2017

Figure 7.2 Sanofi Aventis Net Sales ($mn),2015-2017

Figure 7.3 Sanofi Aventis Net Sales by Segments ($mn),2015-2017

Figure 7.4 Daiichi Sankyo Net Revenues: ($mn), (2015-2017)

Figure 7.5 Novartis Revenue ($bn), 2017

Figure 7.6 Novartis Pharmaceutical by Business Segment: Revenue Share (%),2017

Figure 7.7 Pfizer Revenue ($mn): 2015- 2017

Figure 7.8 Merck & Co. Revenue ($mn): 2015- 2017

Figure 7.9 Boehringer Ingelheim & Co. Revenue ($mn): 2016- 2017

Figure 7.10 United Therapeutics Revenue ($mn): 2015- 2017

Figure 8.1. Pulmonary Hypertension Clinical Trials

Figure 8.2. Essential Hypertension Clinical Trials

Actelion Ltd.

Alcon

AstraZeneca

Aventis

Bayer Inc.

Boehringer Ingelheim

CMS

Daiichi Sankyo, Inc.

Elf Aquitaine

Eli Lilly

GlaxoSmithKline

Hoechst and Rhone –Poulenc

Innovative Medicines

Ivax

Janssen Pharmaceuticals

Johnson & Johnson

Labaz

Lek Pharmaceuticals

Merck & Co.

Mylan Pharma

Novartis

Pfizer

R&D NewCo

Sanis Health, Inc.

Sankyo

Sanofi-Aventis

Sanofi-Synthelabo

Takeda Pharmaceuticals

Teva Pharmaceuticals

United Therapeutics

Valeant Pharmaceuticals

Zeneca Group PLC

List of Organisations Mentioned in the Report

American Heart Association

Bureau of Pharma PSUs of India

The National Heart, Lung and Blood Institute

US National Institute of Health

World Health Organization

World Heart Federation

Download sample pages

Complete the form below to download your free sample pages for Global Hypertension Drugs Market 2019-2029

Download sample pages

Complete the form below to download your free sample pages for Global Hypertension Drugs Market 2019-2029

Case studies

Need customized work?

Report overview

Methodology

Client testimonials

Pharmaceutical industry associations

American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia

Connect with us

Visiongain Pharma

Latest Pharma news

Visiongain Publishes Automation in Biopharma Industry Market Report 2023-2033

The global Automation in Biopharma Industry market was valued at US$1,784.1 million in 2022 and is projected to grow at a CAGR of 5.7% during the forecast period 2023-2033.

20 March 2023

READ

Visiongain Publishes eClinical Solutions Market Report 2023-2033

The global eClinical Solutions market was valued at US$8.03 billion in 2022 and is projected to grow at a CAGR of 13.09% during the forecast period 2023-2033.

17 March 2023

READ

Visiongain Publishes Therapeutic Respiratory Devices Market Report 2023-2033

The global Therapeutic Respiratory Devices market was valued at US$59.49 billion in 2022 and is projected to grow at a CAGR of 8.02% during the forecast period 2023-2033.

15 March 2023

READ

Visiongain Publishes Regenerative Medicine Market Report 2023-2033

The global Regenerative Medicine market was valued at US$ 50.37 billion in 2022 and is projected to grow at a CAGR of 18.40% during the forecast period 2023-2033.

10 March 2023

READ

Industries > Pharma > Global Hypertension Drugs Market 2019-2029

Back to Pharma Reports

Global Hypertension Drugs Market 2019-2029

Angiotensin II Receptor Blockers (ARBs), Angiotensin-converting Enzyme (ACE) Inhibitors, Beta Blockers, Calcium Channel Blockers (CCBs), Diuretics, Fixed-dose Combinations (FDCs)

Download sample pages

Related reports

Global Defibrillators Market Forecast 2019-2029

Global Angioplasty Balloons Market 2019-2029

Global Asthma & COPD Therapies Market 2019-2029

Generic Drugs Market Forecast 2019-2029

Indian Pharmaceutical Market Forecast 2019-2029

Global Pulmonary/Respiratory Drug Delivery Market Forecast 2019-2029

Pharma Leader Series: Top Generic Drug Producers Market Forecast 2019-2029

Download sample pages

Share

Connect with us

Latest Pharma news

Visiongain Publishes Automation in Biopharma Industry Market Report 2023-2033

Visiongain Publishes eClinical Solutions Market Report 2023-2033

Visiongain Publishes Therapeutic Respiratory Devices Market Report 2023-2033

Visiongain Publishes Regenerative Medicine Market Report 2023-2033

Our Clients